1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
North America Biodefense Market to 2027 - Regional Analysis and Forecasts by North America Biodefense Market to 2027 - Regional Analysis and Forecasts by Product ; and Country

North America Biodefense Market to 2027 - Regional Analysis and Forecasts by North America Biodefense Market to 2027 - Regional Analysis and Forecasts by Product ; and Country

  • March 2020
  • 134 pages
  • ID: 5887378
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

The North American biodefense market is estimated to reach US$ 3,357.83 Mn by 2027 from US$ 1,569.29 Mn in 2019; it is projected to grow at a CAGR of 10.1% from 2019 to 2027. The growth of the biodefense market is primarily ascribed to the presence of favorable government initiatives and increase in the number of naturally occurring outbreaks. However, the limited reach of biodefense organizations is one of the major factors restraining the growth of the market. On the other hand, increasing adoption of technologies is expected to have a positive impact on the growth of the North American biodefense market in the coming years.
Biodefense refers to the measures taken to restore biosecurity of a group of organisms that are subject to, or are likely to be subject to, biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide medical surge.
Every year, the governments of North American countries spend heavy amounts on the R&D of vaccines to stay prepared for any bioterrorism attacks.For instance, in 2018, the US government released the National Biodefense Strategy and Implementation Plan, the National Security Strategy, the National Defense Strategy, and the National Counterterrorism Strategy, and the National Counter WMD Strategy, all of which include biosecurity and biodefense.

In addition, the US government is also preparing for Global Health Security Strategy and supporting the development of a 2024 framework of the Global Health Security Agenda, which involves prevention, detection, and response to natural, accidental, and intentional biological threats.

The Executive Order 13887, “Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health,” focuses on creating the National Influenza Vaccine Task Force to reform the domestic influenza vaccine enterprise in the US and also guides certain federal agencies to make specific actions toward achieving the goal.The Order provides budget of US$ 95 million that was higher than that compared to the 2020 enacted level, across Health and Human Services (HHS) for influenza vaccine manufacturing infrastructure and innovation, advanced research and development of improved vaccines, therapeutics and diagnostics, international pandemic preparedness, and improved vaccine coverage nationwide.

Also, the budget covers the HHS biodefense and emergency preparedness procurement through the BioShield program and the Strategic National Stockpile. Further, it includes the budget of US$ 175 million, with a hike of US$ 50 million compared to the 2020 enacted level to support the global health security activities of the Centers For Disease Control and Prevention (CDC).
In 2004, the United States Congress passed the Project BioShield Act, calling for USD 5 billion investments for purchasing vaccines, which can be used in the event of bioterrorist attacks.This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use.

Various biosecurity-related initiatives have been planned, particularly in the matured markets, such as North America.For example, in 2017, more than 50 public and private sector biosecurity stakeholders engaged in a meeting in Johns Hopkins Center, Washington DC, for making recommendations toward the National Biodefense Strategy and Implementation Plan.

As the government engages in the consolidation of current and future policies, the pharmaceutical companies operating in the biodefense market have considerable opportunities to expand and be prepared for bioterrorism. For instance, Spero Therapeutics, an antibiotic developer, has received US$ 15.7 million in federal research funding from Biomedical Advanced Research and Development Authority for its oral carbapenem-class candidate, SPR994. The funding was meant to be directed toward evaluating the drug’s effectiveness against biological threats, including anthrax, plague, and melioidosis. In addition, Biomedical Advanced Research and Development Authority also includes provisions for up to an additional US$ 28.5 million over the next five years, and it would also support Spero’s clinical development of SPR994, which is effective against complicated urinary tract infections caused by drug-resistant bacteria.
In 2019, the anthrax segment accounted for the largest market share in the North American biodefense market, based on product, that further estimated to mark the highest CAGR in the market during 2020–2027.
A few of the significant primary and secondary sources referred to while preparing this report on the biodefense market include the CDC, Food and Drug Administration (FDA), Health and Human Services (HHS), National Health Service (NHS), and Nuclear Threat Initiative (NTI).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Diphtheria - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 85 pages

Diphtheria - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria – Pipeline Review, H1 2020, provides an overview of the Diphtheria (Infectious ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on